Advertisement

Topics

Mattessich Starts as New Ocular CEO, Trims Staff in Cost-Saving Move

14:35 EDT 2 Aug 2017 | Xconomy

Antony Mattessich has formally started as CEO of Ocular Therapeutix and his first move as top executive is culling the company’s headcount by 19 percent. Bedford, MA-based Ocular (NASDAQ: OCUL), whose eye drug delivery device was recently rejected by the FDA, announced last month that Mattessich would succeed Amarpreet Sawhney as CEO. Upon the change, […]

Original Article: Mattessich Starts as New Ocular CEO, Trims Staff in Cost-Saving Move

NEXT ARTICLE

More From BioPortfolio on "Mattessich Starts as New Ocular CEO, Trims Staff in Cost-Saving Move"

Quick Search
Advertisement
 

Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...